← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
126	GRML 126 Greenland Mines Ltd GRML $83.3M	–	–	–	–
127	GTH 127 DELISTED Genetron Holdings Limited ADS GTH	–	–	–	–
128	128 Fractyl Health GUTS $55.7M	–	–	–	–
129	129 Franklin Genomic Advancements ETF HELX $29.8M	–	–	–	–
130	130 iShares Genomics Immunology and Healthcare ETF IDNA $318M	–	–	–	–
131	131 Immix Biopharma IMMX $722M	–	–	–	–
132	132 Immatics IMTX $1.08B	–	–	–	–
133	133 IN8bio INAB $12M	–	–	–	–
134	134 MiNK Therapeutics INKT $51.8M	–	–	–	–
135	135 INmune Bio INMB $46.1M	–	–	–	–
136	136 Century Therapeutics IPSC $264M	–	–	–	–
137	KRBP 137 DELISTED Kiromic BioPharma, Inc. Common Stock KRBP	–	–	–	–
138	138 Korro Bio KRRO $132M	–	–	–	–
139	139 Krystal Biotech KRYS $9.81B	–	–	–	–
140	140 Kyverna Therapeutics KYTX $366M	–	–	–	–
141	141 Legend Biotech LEGN $3.84B	–	–	–	–
142	LGVN 142 Longeveron LGVN $5.04M	–	–	–	–
143	143 Lunai Bioworks LNAI $4.01M	–	–	–	–
144	LOGC 144 DELISTED LogicBio Therapeutics, Inc. Common Stock LOGC	–	–	–	–
145	145 Lexeo Therapeutics LXEO $227M	–	–	–	–
146	146 Lyell Immunopharma LYEL $205M	–	–	–	–
147	147 Mustang Bio MBIO $2.88M	–	–	–	–
148	148 DELISTED 23andMe Holding Co ME	–	–	–	–
149	149 MeiraGTx Holdings MGTX $940M	–	–	–	–
150	150 Metagenomi Therapeutics MGX $32.1M	–	–	–	–